Acetylcholinesterase inhibition and insulin resistance in late onset Alzheimer's disease

International Psychogeriatrics

Volumn 21, Issue 6, 2009, Pages 1127-1133

  Isik, Ahmet Turan ^a   Bozoglu, Ergun ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Alzheimer's; Elderly; Galantamine; Insulin resistance

Indexed keywords

ACETYLCHOLINESTERASE; GALANTAMINE; INSULIN;

AGED; AGING; ALZHEIMER DISEASE; ARTICLE; CLINICAL EVALUATION; COGNITION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG DOSE TITRATION; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; GERIATRIC ASSESSMENT; HUMAN; INSULIN RESISTANCE; LATE ONSET ALZHEIMER DISEASE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; ONSET AGE; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BLOOD GLUCOSE; BRAIN; CHOLINESTERASE INHIBITORS; FEMALE; GALANTAMINE; GERIATRIC ASSESSMENT; HUMANS; INSULIN RESISTANCE; MALE; MENTAL STATUS SCHEDULE; NOOTROPIC AGENTS; PSYCHOMETRICS;

EID: 75149185825     PISSN: 10416102     EISSN: 1741203X     Source Type: Journal    
DOI: 10.1017/S1041610209990664     Document Type: Article

References (31)

1. Bernstein, H. G. et al. (1999). Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques. Neuroscience Letters, 263, 161-164. doi:10.1016/S0304-3940(99)00135-4. (Pubitemid 29158953)
2. Bigl, M., Beck, M., Bleyl, A. D., Bigl, V. and Eschrich, K. (2000). Altered phosphofructokinase mRNA levels but unchanged isoenzyme pattern in brains from patients with Alzheimer's disease. Molecular Brain Research, 76, 411-414. doi:10.1016/S0169-328X(00)00019-X. (Pubitemid 30179780)
3. Bigl, M., Apelt, J., Eschrich, K. and Schliebs, R. (2003). Cortical glucose metabolism is altered in aged transgenic Tg2576 mice that demonstrate Alzheimer plaque pathology. Journal of Neural Transmission, 110, 77-94. doi: 10.1007/s00702-002-0772-X.
4. Craft, S., Reger, M. A. and Baker, L. D. (2006). Insulin resistance in Alzheimer's disease: A novel therapeutic target. Alzheimer's Disease and Related Disorders Annual, 5, London, Taylor and Francis (pp. 111-133).
5. Cummings, J. L., Schneider, L., Tariot, P. N., Kershaw, P. R. and Yuan, W. (2004). Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. American Journal of Psychiatry, 161, 532-538.
6. Das, U. N. (2007). Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 13, RA214-221.
7. Ezoulin, M. J., Ombetta, J. E., Dutertre-Catella, H., Warnet, J. M. and Massicot, F. (2008). Antioxidative properties of galantamine on neuronal damage induced by hydrogen peroxide in SK-N-SH cells. Neurotoxicology, 29, 270-277. doi:10.1016/j.neuro.2007.11.004.
8. Ferrara, C. M. and Goldberg, A. P. (2001). Limited value of the homeostasis model assessment to predict insulin resistance in older men with impaired glucose tolerance. Diabetes Care, 24, 245-249. doi: 10.1210/jc.2005-1803.
9. Fr̈olich, L. et al. (1998). Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. Journal of Neural Transmission, 105, 423-438. doi: 10.1007/s007020050068. (Pubitemid 28365027)
10. Gasparini, L., Netzer, WJ., Greengard, P. and Xu, H. (2002). Does insulin dysfunction play a role in Alzheimer's disease? Trends in Pharmacological Sciences, 23, 288-293. doi:10.1016/S0165-6147(02)02037-0. (Pubitemid 34655735)
11. Gokcel, A. et al. (2003). Detection of insulin resistance in Turkish adults: A hospital-based study. Diabetes, Obesity and Metabolism, 5, 126-130. doi: 10.1046/j.1463-1326.2003. 00253.X.
12. Ho, L. et al. (2004). Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB Journal, 18, 902-904. doi: 10.1096/fj.03-0978fje.
13. Houstis, N., Rosen, E. D. and Lander, E. S. (2006). Reactive oxygen species have a causal role in multiple forms of insulin resistance, Nature, 440, 944-948. doi:10.1038/ nature04634.
14. Hoyer, S. (1998). Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis. Journal of Neural Transmission, 105, 415-422. doi: 10.1007/s007020050067. (Pubitemid 28365026)
15. Hoyer, S. (2004). Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. European Journal of Pharmacology, 490, 115-125. doi: 10.1016/j.ejphar.2004. 02.049 (Pubitemid 38482165)
16. Isik, A. T. et al. (2007). Is there any relation between insulin resistance and cognitive function in the elderly? International Psychogeriatrics, 19, 745-756. doi: 10.1017/ S1041610207005406. (Pubitemid 47037102)
17. Isik, A. T., Celik, T., Bozoglu, E. and Doruk, H. (2009). Trospium and cognition in patients with late onset Alzheimer disease. Journal of Nutrition, Health and Aging. (In press).
18. Leibson, C. L. et al. (1997). Risk of dementia among persons with diabetes mellitus: A population-based cohort study. American Journal of Epidemiology, 145, 301-308. doi:10.1111/j.1749-6632.1997.tb48496.X. (Pubitemid 27478066)
19. Li, X., Zhou, Z. G.,Qi, H. Y., Chen, X. Y. andHuang,G. (2004). Replacement of insulin by fasting C-peptide in modified homeostasis model assessment to evaluate insulin resistance and islet beta cell function. Journal of Central South University. Medical Sciences, 29, 419-423.
20. Mesulam, M. (2004). The cholinergic lesion of Alzheimer's disease: pivotal factor or side show? Learning and Memory, 11, 43-49. doi: 10.1101/lm.69204. (Pubitemid 38167057)
21. Pilcher, H. (2006). Alzheimer's disease could be "type 3 diabetes", Lancet Neurology, 5, 388-389. doi:10.1016/ S1474-4422(06)70434- 70443
22. Randel, E. W.,Mathews,M. S., Zhang, H., Seraj, J. S. and Sun, G. (2005). Relationship between serum butyrylcholinesterase and the metabolic syndrome. Clinical Biochemistry, 38, 799-805. doi:10.1016/j.clinbiochem. 2005.04.008.
23. Reyes, A. E. et al. (2004). Acetylcholinesterase-Abeta complexes are more toxic than Abeta fibrils in rat hippocampus: effect on rat beta-amyloid aggregation, laminin expression, reactive astrocytosis, and neuronal cell loss. American Journal of Pathology, 164, 2163-2174.
24. Samochocki, M. et al. (2000). Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurologica Scandinavica. 176, 68-73. doi: 10.1124/jpet.103.063586.
25. Sharma, P. et al. (2006). Mining literature for a comprehensive pathway analysis: A case study for retrieval of homocysteine related genes for genetic and epigenetic studies. Lipids in Health and Disease. 5, 1. doi: 10.1186/ 1476-511X-5-11
26. Stolk, R. P. et al. (1997). Insulin and cognitive function in elderly population: the Rotterdam Study. Diabetes Care, 20, 792-795.
27. Taubes, G. (2003). Neuroscience: insulin insults may spur Alzheimer's disease. Science, 301, 40-41. doi: 10.1126/science.301.5629.40. (Pubitemid 36801550)
28. Terry, A. V. Jr and Buccafusco, J. J. (2003). The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: Recent challenges and their implications for novel drug development. Journal of Pharmacology and Experimental Therapeutics, 306, 821-827. doi: 10.1124/ jpet.102.041616.
29. Watson, G. S. and Craft, S. (2003). The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs, 17, 27-45.
30. Wilkinson, D. G., Francis, P. T., Schwam, E. and Payne-Parrish, J. (2004). Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs and Aging, 21, 453-478.
31. Yaffe, K. et al. (2004). The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA, 292, 2237-2242. doi:10.1001/jama.292.18.2237. (Pubitemid 39473161)